Previous 10 | Next 10 |
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial plan for its lead psychedelic drug for the treatment of major depressive disorder after r...
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today the agenda for its virtual Capital Markets Day on 12 October 2022 at 8:00 ...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 – Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminali...
LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at Jefferies Innovation in Mental He...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change after a psychedelic drug experience and a non-d...
LONDON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming investor events as follows:...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This week in our Hypergrowth Investing podcast , we’re talking about my Big Three investing themes for the rest of the year (and beyond). You’ve probably heard me talk about each of these at one poin...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perce...
August 2022 – just another month in the evolving psychedelics industry featuring another issue with Compass Pathways . The new legal spat comes on the heels of Compass being granted two patents for their form of psilocybin: U.S. Patent No. 10,954,259 granted on Marc...
One of the big advantages individual investors have over fund managers is that no one is looking over their shoulders for quick results. Individuals can invest for the long term; they can hold through volatility and watch their investments provide massive returns over decades. In this r...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...